The prostate becomes increasingly susceptible to various pathological alterations including benign proliferative lesions, inflammatory conditions, premalignant changes, and malignant neoplasms, with the advancing age, particularly after the fifth decade of life , all of which contribute substantially to morbidity in elderly men. [1,2]
Among prostatic disorders, benign prostatic hyperplasia (BPH), prostatitis, and carcinoma of the prostate are the most commonly encountered lesions. BPH is a non-neoplastic enlargement predominantly involving the transition zone and represents the leading cause of lower urinary tract symptoms in aging males. Prostatitis includes a spectrum of inflammatory conditions ranging from acute bacterial infection to chronic granulomatous inflammation, often mimicking malignancy clinically and biochemically. Prostatic carcinoma, most commonly acinar adenocarcinoma, usually arises in the peripheral zone and remains a major contributor to cancer-related morbidity and mortality worldwide.[3]
Serum prostate-specific antigen (PSA) is the most widely used biochemical marker for evaluating prostatic diseases. PSA is a glycoprotein serine protease produced by secretory epithelial cells of the prostate and plays a physiological role in semen liquefaction. Elevation of serum PSA occurs due to disruption of normal prostatic architecture caused by hyperplasia, inflammation, infarction, or malignant transformation. Hence, PSA is organ-specific but not cancer-specific. While PSA levels below 4 ng/mL are generally considered normal, significant overlap exists between benign and malignant lesions, particularly within the diagnostic “gray zone” of 4–10 ng/mL. [4-6]
Despite its widespread utility, PSA screening has limitations because of poor specificity and the risk of overdiagnosis. Therefore, PSA interpretation should always be correlated with clinical findings, imaging, and histopathological examination, which remains the gold standard for definitive diagnosis of prostatic lesions. Histopathological grading using the Gleason scoring system and ISUP Grade Groups provides important prognostic information and guides therapeutic decisions.[7-10]
Considering the overlap in PSA levels among benign, inflammatory, and malignant lesions, correlation of serum PSA with histopathological findings is clinically important for improving diagnostic accuracy, reducing unnecessary biopsies, and guiding patient management. Therefore, the present study was undertaken to evaluate the histopathological spectrum of prostatic lesions and correlate these findings with serum PSA levels in patients presenting to a tertiary care centre.
Methodology:This study was carried out in the department of pathology at Krishna Vishwa Vidyapeeth, Karad.A total of 80 cases having prostatic lesions were included in this study.Inclusion Criteria: All the surgical specimens of prostate which include transurethral resection of prostate (TURP) and prostatic biopsies received in the Department of Pathology during our study period, from our hospital as well as referrals from other hospitals were included in this study.Exclusion Criteria: Specimens with no clinical details and unknown serum PSA levels were excluded.Ethical Clearance: Ethical clearance for the study was obtained from Institutional Ethical Committee.
Data Collection:Details of the patient included age, thorough history like presenting complaints and other investigations and pre-operative serum PSA levels were all recorded on predesigned and pretested proforma.PSA values of the patients before the surgical procedures were recorded(figure 1). Quantitative estimation of the total serum PSA was done using Immuno Enzymatic Assay.
Collection of specimens and grossing techniques-histopathological specimens of prostate biopsy and transurethral resection of prostate (TURP)were studied. All the specimens were fixed in 10% formalin,slides were stained with Hematoxylin and Eosin (H&E).
Study included 80 cases of prostatic lesions. The age of the patients in the present study ranged from 41 to 85 years with a mean age of 65.83 ± 9.41 years. On clinical presentation, increased frequency of micturition was the most common presenting complaint seen in 72 cases (90.0%), followed by hesitancy or poor urinary stream in 70 cases (87.50%). Acute urinary retention was observed in 26 cases (32.50%), while dysuria was present in 19 cases (23.75%). Haematuria was the least common symptom, noted in 5 cases (6.25%). Overall, lower urinary tract symptoms constituted the predominant clinical presentation.
Table 1: Distribution of Prostatic Lesions on Histopathology
|
Histopathological diagnosis |
Number of cases |
Percentage (%) |
|
|
Benign prostatic hyperplasia (± chronic inflammation) |
63 |
78.75 |
|
|
Xanthogranulomatous Prostatitis |
03 |
03.75 |
|
|
High grade PIN (HGPIN) |
07 |
08.75 |
|
|
Adenocarcinoma prostate |
07 |
08.75 |
|
|
Total |
80 |
100 |
Benign prostatic hyperplasia with inflammation was the most common histopathological diagnosis observed in 63 cases (78.75%)( Figure 2,4). High-grade prostatic intraepithelial neoplasia and adenocarcinoma prostate were each seen in 7 cases (8.75%) (Figure 3,5). Xanthogranulomatous prostatitis was the least common lesion noted in 3 cases (3.75%). Thus, benign lesions formed the majority of prostatic lesions in this study[Table 1]. Among the seven cases of prostatic adenocarcinoma, acinar adenocarcinoma was the predominant histological subtype seen in 5 cases (71.43%), while signet ring cell carcinoma was observed in 2 cases (28.57%).Higher Gleason grade groups predominated in the present study. Grade Group 4 and Grade Group 5 were the most common, each observed in 2 cases (28.57%), while Grade Groups 1, 2 and 3 were seen in one case each (14.29%).
Figure 2:Photomicrograph showing prostatic epithelial hyperplasia composed of variably sized glandular structures lined by basal and secretory cells,glandular dilatation with papillary infoldings,cysts,with corpora amylacea seen (H&E 100X).
Figure 3: Prostate adenocarcinoma shows prostatic tissue infiltrated by crowded, small atypical glands with infiltration in surrounding stroma. The glands are lined by multi layer of neoplastic cells with enlarged, hyperchromatic nuclei (H&E 100X).
Figure 4: Prostatic adenocarcinoma with Signet ring cell component (H&E, 100X).
Figure 5-infiltration of prostatic stroma predominant by lymphocytes-Chronic prostatitis with BPH. (H&E, 100X)
Most patients had serum PSA levels between 4–10 ng/mL comprising 42 cases (52.50%). PSA levels less than 4 ng/mL were seen in 19 cases (23.75%), levels between 10–20 ng/mL in 13 cases (16.25%), and levels greater than 20 ng/mL in 6 cases (7.50%). [Fig 1]
Figure 1: Serum PSA levels in Prostatic Lesions.
A progressive rise in mean serum PSA levels was observed from benign to malignant lesions. The lowest mean PSA was seen in benign prostatic hyperplasia (5.19 ± 3.22 ng/mL), followed by HGPIN and inflammatory lesions, while the highest mean PSA was observed in adenocarcinoma (64.11 ± 34.41 ng/mL). The difference in mean serum PSA levels among the histopathological groups was statistically significant (One-way ANOVA, P < 0.001). [Table 2].
Table 2: Correlation of Serum PSA with histopathological Diagnosis of prostate lesions
|
Histopathological Diagnosis |
Mean PSA (ng/mL) |
PSA range (nanograms per milliliter:ng/mL) |
|
BPH |
5.19 ± 3.22 |
2.5 – 12.2 |
|
HGPIN |
10.62 ± 3.93 |
4.5 – 15.2 |
|
Xanthogranulomatous Inflammation |
17.2 ± 5.71 |
11 – 29.3 |
|
Adenocarcinoma prostate |
64.11 ± 34.41 |
8.9 – 115 |
Prostatic lesions are an important cause of urological morbidity in elderly males and include a wide spectrum of benign, inflammatory, premalignant, and malignant conditions. Accurate diagnosis and classification are essential for proper management and prognostication. The study was undertaken to evaluate the histopathological spectrum of prostatic lesions and correlate them with clinical findings and serum PSA levels. Special emphasis was given to prostatic neoplasms using the WHO 2022 classification to improve diagnostic accuracy and clinicopathological correlation.
Age Distribution
The age of patients ranged from 41 to 85 years, with a mean age of 65.83 ± 9.41 years, and the majority (41.25%) in the 61–70 years group, followed by 25% each in 51–60 and 71–80 years groups. This age predominance suggests that prostatic lesions are more commonly encountered in elderly males in our study population., with fewer cases in younger adults (3.75% in 41–50 years) and elderly (>80 years at 5%).
Age-Lesion Relation
BPH with inflammation peaked in 61–70 years (38.10%), HGPIN/adenocarcinoma also higher in older groups but no statistical link (p=0.32); >80 years showed only benign. Although lesions were more common in older age groups, no statistically significant association between age and lesion type was found.Sharma et al. [11] observed that the majority of prostatic lesions (BPH predominant) in 61–70 years (28%) and 51–60 years (22.66%), closely mirroring our peak incidence and emphasizing elderly burden, though their mean age was slightly lower due to a larger younger cohort. Tyagi et al. [12] reported a mean age of 69.7 years for prostate lesions in their study, aligning with our findings of older age predominance, but noted higher North Indian incidence compared to South, possibly explaining minor regional differences in our Delhi-based study. Khalid et al. [13] observed similar peaks in 60-69 years (30%) for biopsies, supporting age as a consistent risk across Indian centers. Patel et al. [14] confirmed elderly dominance (mean 68 years) in incidental cancers, paralleling our distribution but with higher malignancy in TURP specimens.
Clinical Presentation
Patients predominantly presented with lower urinary tract symptoms:LUTS, with increased frequency of micturition in 90%, hesitancy/poor stream in 87.5%, acute urinary retention in 32.5%, dysuria in 23.75%, and hematuria least at 6.25%. Irritative and obstructive symptoms dominated, reflecting urethral compression by prostatic enlargement,Acute urinary retention was observed in approximately one-third of cases, indicating advanced urinary obstruction in some patients.
Kumar N et al. [15] observed LUTS as the primary presentation in 92% of localized prostate cases, similar to our high LUTS prevalence, though their metastatic cohort had added bony pain unlike our predominantly benign group with minimal systemic symptoms. Khan et al. [16] found dysuria (64%) and other LUTS common, corroborating our frequency and hesitancy rates, but reported higher prostate cancer yield (22.4%) in LUTS patients, suggesting our lower malignancy rate may stem from earlier biopsy intervention. Pushpa N et al. [17] Reported similar findings.
Histopathological interpretations
Most cases (41.25%) were in 61–70 years across categories; BPH with inflammation dominated (63 cases, peaking at 38.10% in 61–70 years), followed by rare xanthogranulomatous inflammation (3 cases), HGPIN (7 cases), and adenocarcinoma (7 cases).No statistically significant association was observed between age group and type of lesion (p = 0.32)
Shetty P et al. [18] reported benign lesions (BPH 82%, prostatitis 60% associated) at 88-92%, akin to our BPH/inflammation majority, with similar age peaks, though higher benign proportion reflects their biopsy focus versus our comprehensive lesions. Khalid et al. [13] found BPH (32.67%), prostatitis (18.67%), and malignancy (11.33%), paralleling our distributions, but higher PIN (in 53.33% BPH), possibly due to detailed epithelial subtyping absent in our analysis.
Prostatic Adenocarcinoma Variants and Gleason Groups
Prostate cancer is suspected in individuals who present with a hard, enlarged prostate or a palpable nodule on physical examination, along with elevated PSA levels on laboratory testing. Confirmation of the diagnosis requires a biopsy followed by histological evaluation. The Gleason grading system is the cornerstone in the pathological evaluation of prostate cancer, which is largely based on architectural patterns.
Among 7 adenocarcinomas, acinar type prevailed (71.43%), with signet ring cell in 28.57%; Gleason Grade Groups 4 and 5 each at 28.57%, Groups 1-3 at 14.29% each. Higher Gleason grade groups were more frequent in our series.
Singh et al. [19] noted Gleason Group 3 as most common (35%), differing from our higher Groups 4-5, likely due to their larger adenocarcinoma cohort detecting more intermediates, but both highlight advanced grades in Indian presentations. Reddy et al. [20] detailed signet ring variants as aggressive per WHO, aligning with our high-grade correlation and poor differentiation in 28.57% cases.
Serum PSA Levels
Most patients (52.5%) had PSA 4–10 ng/mL, 23.75% <4 ng/mL, 16.25% 10–20 ng/mL, and 7.5% >20 ng/mL. Majority of cases showed PSA levels in the 4–10 ng/mL range, corresponding to the predominance of benign lesions in our study.
Patel et al. [14] reported median PSA 5 ng/mL for BPH , rising to 81 ng/mL in adenocarcinoma, matching our pattern though their cut-off was 19.5 ng/mL for malignancy. Parvathaneni et al. (2025) found <4 ng/mL in 48.38% benign cases, comparable to our 23.75%, with all malignancies >10 ng/mL, supporting our distribution but higher malignancy PSA threshold due to wider ranges. Khan et al. [16] observed 55% in 4-10 ng/mL for benign lesions, closely aligning with our majority, while malignant cases exceeded 20 ng/mL in 40%. Khalid et al. [13] noted similar mild elevations (mean 7.2 ng/mL benign), emphasizing PSA's overlap in Indian cohorts with BPH predominance. Changes in PSA over time, such as PSA velocity, PSA doubling time, and PSA density can help assess prostate cancer risk. Stable PSA levels may allow careful monitoring instead of immediate repeat biopsy in selected patients.
PSA-Histopathology Correlation of prostate lesions
Mean PSA rose progressively: BPH 5.19 ± 3.22 ng/mL, HGPIN 10.62 ± 3.93 ng/mL, xanthogranulomatous 17.2 ± 5.71 ng/mL, adenocarcinoma 64.11 ± 34.41 ng/mL (highly significant, p<0.001, ANOVA). A progressive rise in PSA levels was observed from benign to malignant lesions, with high variability in malignancy linking to grade/volume. Kumar N et al. [15] observed similar rises (benign low, malignant >10 ng/mL in 100%), corroborating our correlation, though exact means varied by cohort size. Pushpa N et al. [17] found medians escalating from 5 ng/mL (BPH) to 81 ng/mL (adenocarcinoma), aligning closely, with statistical significance emphasizing PSA's diagnostic value across lesion severity in Indian men. Khan et al. [16] reported progressive elevation (BPH 6.1 ng/mL to ca prostate 45 ng/mL, p<0.01), mirroring our gradient but lower peaks due to earlier detection. Khalid et al. [13] confirmed highly significant ANOVA (p<0.001) with adenocarcinoma means at 52 ng/mL, supporting PSA as a reliable discriminator in resource-limited Indian settings. .
The prostate tissue biopsy remains the gold standard for the definitive diagnosis of prostate lesions. Histopathological evaluation confirms the precise nature of the lesion and enables Gleason scoring, which assesses the architectural pattern and aggressiveness of malignant cells.The degree of elevation of PSA along with clinical correlation aid in diagnosis of prostatic lesions.[20] Most definitive role of PSA appears to be in diagnosing recurrences after adequate surgical treatment, and in evaluating response to treatment.[21]Its use as a screening method to detect prostate cancer is also common, although controversial. It has been established that digital rectal exam and PSA are the most useful front-line methods for assessing an individual’s risk of prostate cancer.[22].
The present study observed that prostatic lesions occur predominantly in elderly males and are mainly benign in nature, with benign prostatic hyperplasia forming the major component. However, a significant proportion of premalignant and malignant lesions is encountered in advancing age. Serum PSA shows a progressive rise from benign to malignant conditions and correlates significantly with histopathological severity and Gleason grade groups. Although PSA alone is not diagnostic, it serves as an effective screening and risk-stratification marker, while histopathological examination remains the gold standard for definitive diagnosis. Hence, combined evaluation of clinical findings, serum PSA levels and histopathology provides a reliable approach for early detection and appropriate management of prostatic lesions.
Abbresions: Prostate-Specific Antigen:PSA, Transrectal ultrasound-guided :TRUS,Benign Prostatic Hyperplasia :BPH,Prostatic Intraepithelial Neoplasia: PIN,High-grade prostatic intraepithelial neoplasia: HGPIN:International Society of Uropathology :ISUP,lower urinary tract symptoms :LUTS
[1] Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell Walsh Urology. 10th ed. Philadelphia: Elsevier Saunders; 2012. p. 2533-763.
[2] Wadgaonkar AR, Patil AA, Mahajan SV, Yengantiwar RP. Correlation of serum prostate-specific antigen (PSA) level in various prostate pathology in elderly men. Int J Basic Appl Med Sci 2013; 3:274-81.
[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–249.
[4] SC Mishra, B Sahu, SS Kar, S Dixit, AP Dash. Clinicopathological correlation of various prostatic lesions with serum prostate-specific antigen level–A hospital-based cross-sectional study. National Journal of Physiology, Pharmacy and Pharmacology. 2023; 13 (6):1323-1323.
[5] Jayapradeep DP, Prakash VB, Philipose TR, Pai MR. Histomorphologic correlation of PSA levels in prostatic pathology. Natl J Lab Med. 2017;6(4):28-32.
[6] Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol.2012;3(2):120-9.
[7] Agosti V, Munari E. Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects. Asian J Androl. 2024,1;26(6):575-581.
[8] Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA., Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-52
[9] WHO Classification of Tumours Editorial Board. WHO Classification of the Urinary and Male Genital Tumours. 5th ed. Lyon, France: WHO Classification of Tumours Editorial Board; 2022.
[10] Sharma M, Jamaiyar A. Exploration of Serum Prostatic Specific Antigen Level in Enlarged Prostate with its Histopathological Correlation. Journal of Pharmacy and Bioallied Sciences. 2022,1;14(Suppl 1):S880-3.
[11] Tyagi S, Tyagi N, Choudhury A, Gupta G, Zahra MM, Rahin SA. Identification and classification of prostate cancer based on improved convolution neural network. BioMed Research International. 2022;2022(1):9112587.
[12] Khalid M, Khan MM, Jalily QA, Mummareddi DE, Sirangi S, Dande SNSA. A hospital-based study of prostate biopsy results in Indian males. J Family Med Prim Care. 2024;13(3):984-989.
[13] Patel K, Jani H, Goswami J. Correlation of serum PSA level with histopathological findings of prostate specimens in tertiary care hospital. International Journal of Clinical and Diagnostic Pathology. 2024;7(3):159-163.
[14] Kumar N, Vasudeva P, Kumar A, Singh H. Prospective randomized comparison of monopolar TURP, bipolar TURP and photoselective vaporization of the prostate in patients with benign prostatic obstruction: 36 months outcome.Lower Urinary Tract Symptoms. 2018;10(1):17-20.
[15] Khan F, Kakar MH, Sarwar MA, Aslam MM, Qureshi HA, Murtaza HB. To determine the frequency of prostate cancer in patients of suspicion of prostate cancer. The Professional Medical Journal. 2025, 3;32(02):143-50.
[16] Pushpa N, Goyal R, Bhamu S. Histopathological spectrum of prostatic lesions and their correlation with serum prostate specific antigen levels. Asian Journal of Pharmaceutical and Clinical Research. 2024;17(2):36-9.
[17] Shetty P, Singh B.M.K, Shetty T, Bishnu A. Correlation of prostate specific antigen level with histopathological findings in patients with prostatic disease.Trop J Path Micro 2016;2(3):152-158
[18] Singh M, Jha R, Melamed J, Shapiro E, Hayward SW, Lee P. Stromal androgen receptor in prostate development and cancer. The American journal of pathology. 2014 1;184(10):2598-607.
[19] Reddy RR, Jagannathan NR. Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer. Indian Journal of Urology. 2022, 1;38(2):99-109.
[20] W Khatib, S Jagtap, R Demde, DB Shukla, T Bisht. Clinicopathological study of prostate lesions-A one year study.Int J Med Res Health Sci.2016, 5 (5), 183-6.
[21] Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol. 2012;3(2):120-9.
[22] Matthew B Gretzer, Alan W Partin. PSA Levels and the Probability of Prostate Cancer on Biopsy. European Urology Supplements.2002,1,6:21-27.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications